Abstract
Abstract
Background
Toll-like receptors (TLRs) are an important family of receptors that constitute the first line of defense system against microbes. They can recognize both invading pathogens and endogenous danger molecules released from dying cells and damaged tissues and play a key role in linking innate and adaptive immunity. TLRs are widely distributed in both immune and other body cells. The expressions and locations of TLRs are regulated in response to specific molecules derived from pathogens or damaged host cells. The binding of ligands to TLR activates specific intracellular signaling cascades that initiate host defense reactions. Such binding is ligand-dependent and cell type-dependent and leads to production of pro-inflammatory cytokines and type 1 interferon. TLR-dependent signaling pathways are tightly increased during innate immune responses by a variety of negative regulators. Overactivation of TLRs can ultimately lead to disruption of immune homeostasis and thus increase the risk for inflammatory diseases and autoimmune disorders. Antagonists/inhibitors targeting the TLR signaling pathways have emerged as novel therapeutics to treat these diseases.
Aim of work
The present review summarizes the structure, characterizations, and signaling of TLRs and their regulators, as well as describes the implication of TLRs in many diseases with a brief idea about the inhibitors that target TLR signaling pathways.
Conclusion
We conclude that TLRs are the main elements of our immune system, and they should be maintained functioning to keep the integrity of innate immunity. Targeting of TLR signaling represents a new challenge for treatment of many diseases.
Publisher
Springer Science and Business Media LLC
Reference139 articles.
1. Ahmad R, Al-Mass A, Atizado V, Al-Hubail A, Al-Ghimlas F, Bennakhi A, Dermime S, Behbehani K (2012) Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation. J Inflamm 9:48
2. Ahmed S, Moawad M, Elhefny R, Abdullatif M (2016) Is toll like receptor 4 a common pathway hypothesis for development of lung cancer and idiopathic pulmonary fibrosis? Egypt J Chest Dis Tuberc 65(1):289–294
3. Akira S, Takeda K (2004) Toll-like receptor signaling. Nat Rev Immunol 4:499–511. https://doi.org/10.1038/nri1391
4. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801
5. Allam HA, Abd EL-Salam M, Mohammad A, Aboulkhair AG (2015) Clinical value of Toll like receptor 4 and CD14 in children with acute lower respiratory tract infection. Int Biol Biomed J Summer 1(3):90–97
Cited by
325 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献